Recent Updates
Recently added Catalysts

Gabapentin

Phase 4FDA approved

Undisclosed | Small Molecules | Other |Pfizer, Inc.|Trials Updated: Mar 7, 2011

Gabapentin development status

FDA approval on record Oct 9, 1998 as Neurontin
Approval holderViatris
ApplicationNDA020882
Highest phase Phase 4 run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (NCT00584779)
Phase scored for PFEPhase 1
Registered trials 29 across 10 sponsors since Sep 2005

Label indication NEURONTIN ® is indicated for: • Management of postherpetic neuralgia in adults • Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy NEURONTIN is indicated for: • Postherpetic neuralgia in adults ( 1 ) • Adjunctive therapy in the treatment of partial onset seizures, with and without secondary…

Gabapentin target and mechanism

Molecular targetCACNA1H, CACNA2D1, CACNA1C, CACNA2D3, CACNA1S, CACNA2D2
Target classModulator
ModalitySmall Molecules
ChEMBLCHEMBL940

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment19

FDA Designations

No designations recorded

Gabapentin clinical trials

Gabapentin · 1 trial · 1 indication

Phase 1 1
NCT01119222Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male VolunteersHealthy
COMPLETED19 Analytics
PHASE1COMPLETED
Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers
HealthyUnlock trial analytics

Study Endpoints

Primary Endpoints

Average Pain (0-120 Seconds): Cold Pain Test Visual Analog Scale (VAS)
Pre-dose, 1, 1.5, 2, 4, and 8 hours post-dose

Area under the cold pain test Visual Analog Scale (VAS) time curve (AUCcpt 0 to 120 seconds \[sec\]) averaged over the 120 sec for each time point assessed. Participant adjusted 100 millimeter (mm) electronic VAS with range of "no pain" (0) to "maximum pain" (100) at the anchor endpoints of the scale and "moderate pain" at the midpoint. Pain reported while non-dominant hand was placed in thermostatically controlled water bath at 2±1°C for a maximum of 120 sec.

Interpolated Average Pain (0-8 Hours)
Pre-dose to 8 hours post-dose

Interpolated average pain (0 to 8 hours): area under the curve (AUC) of average pain (0 to 120 seconds) recorded at each of the time points taken over 8 hour time period divided by 8.

Secondary Endpoints

Number of Participants With Clinically Significant Findings in Vital Signs
Predose, Day 1, Day 2 each treatment period, follow-up visit (at least 7 days after last dosing)
Number of Participants With Clinically Significant Abnormal Findings on Physical Examination
Pre-dose and follow-up visit (at least 7 days after last dosing)
Number of Participants With Abnormal Findings on Electrocardiogram (ECG)
Pre-dose and follow-up visit (at least 7 days after last dosing)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelCROSSOVER

Treatment Arms

ArmTypeDescription
Gabapentin 1200mgACTIVE_COMPARATOR -
Diphenhydramine 50 mgACTIVE_COMPARATOR -
Morphine 10 mgACTIVE_COMPARATOR -
Placebo formulationsPLACEBO_COMPARATOR -

Interventions

NameTypeDescription
GabapentinDRUGCapsule, single 1200mg dose
DiphenhydramineDRUGTablet, single 50mg dose
MorphineDRUGIV, single 10mg dose
PlaceboDRUGPlacebo formulations (Capsule, tablet, IV to match the active treatments and to be administered in a double-dummy fashion).
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy male volunteers having given consent to participate in the study who have no clinically significant anomalies and whose vital signs are within normal range. * Subject having performed the cold pain test reproducibly ie, if the area under the pain-time curve (AUC) must ...

Countries:Belgium
Unlock Eligibility Criteria

Frequently asked questions about Gabapentin

What is gabapentin?

Gabapentin is a small molecule drug developed by Pfizer, Inc. (ticker PFE). It is being studied in Phase 1 clinical development, and its current development indications are undisclosed. Gabapentin is a modulator that acts on multiple calcium channel targets, including CACNA1H, CACNA2D1, CACNA1C, CACNA2D3, CACNA1S, and CACNA2D2.

What does gabapentin target?

Gabapentin targets the calcium channel proteins CACNA1H, CACNA2D1, CACNA1C, CACNA2D3, CACNA1S, and CACNA2D2. It is classified as a modulator of these targets. This target profile places gabapentin among small molecule drugs that act on voltage-gated calcium channel subunits.

Who makes gabapentin?

Gabapentin is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the company associated with the clinical development of gabapentin as described in its Phase 1 program.

What phase is gabapentin in?

Gabapentin is in Phase 1 clinical development. It is an investigational small molecule and is not described as FDA approved. The Phase 1 program includes one completed trial, and no active trials are currently listed for gabapentin.

What clinical trials is gabapentin in?

Gabapentin has been studied in the Phase 1 trial NCT01119222, titled Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers. The trial was completed in Belgium with 19 enrolled healthy male volunteers aged 18 years and older. It was randomized, double-blind, and placebo-controlled.

Is gabapentin a small molecule drug?

Yes, gabapentin is a small molecule drug. It is a modulator of calcium channel targets including CACNA1H, CACNA2D1, CACNA1C, CACNA2D3, CACNA1S, and CACNA2D2, and it is being developed by Pfizer, Inc. (ticker PFE) in Phase 1 clinical development.